Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Rat (Rattus) PTPRJ Antibodies:
anti-Human PTPRJ Antibodies:
anti-Mouse (Murine) PTPRJ Antibodies:
Go to our pre-filtered search.
Human Monoclonal PTPRJ Primary Antibody for FACS - ABIN4898524
Llinàs, Lázaro, de Salort, Matesanz-Isabel, Sintes, Engel: Expression profiles of novel cell surface molecules on B-cell subsets and plasma cells as analyzed by flow cytometry. in Immunology letters 2010
Show all 2 Pubmed References
Human Monoclonal PTPRJ Primary Antibody for CyTOF, FACS - ABIN4900751
Cabezón, Sintes, Llinàs, Benitez-Ribas: Analysis of HLDA9 mAbs on plasmacytoid dendritic cells. in Immunology letters 2010
Show all 2 Pubmed References
Human Monoclonal PTPRJ Primary Antibody for FACS - ABIN4898523
Rollin, Pouplard, Gratacap, Leroux, May, Aupart, Gouilleux-Gruart, Payrastre, Gruel: Polymorphisms of protein tyrosine phosphatase CD148 influence FcγRIIA-dependent platelet activation and the risk of heparin-induced thrombocytopenia. in Blood 2012
These data support that PTPN22 (show PTPN22 Antibodies) 1858C/T, PTPRJ 2965C/G and 1176 A/C polymorphisms and ACP1 A (show ACP1 Antibodies), B and C alleles are not associated with a higher risk of immune thrombocytopenia P in adults.
Loss of PTPRJ expression may predict an aggressive clinical course in ESCC patients.
The strongest association with frailty was observed in the Protein Tyrosine Phosphatase (show ACP1 Antibodies), Receptor type, J (PTPRJ) (rs1566729, P = 0.001372, beta = 0.09397) gene.
the combination of CD200 (show CD200 Antibodies) and CD148 may have a potential differential diagnostic value in leukemic B-CLPDs, especially between CLL and MCL (show FH Antibodies).
These results demonstrated Ptprj as a physiological enzyme that attenuates insulin (show INS Antibodies) signalling in vivo, and indicate that an inhibitor of Ptprj may be an insulin (show INS Antibodies)-sensitizing agent.
CD148 tyrosine phosphatase promotes e-cadherin (show CDH1 Antibodies) cell adhesion.
The studies suggest induction of MMP-9 (show MMP9 Antibodies) expression promoted by DEP-1 deficiency.
Moderate expression of DEP-1 was associated with the increased relapse.
C33A cells lacking PTPRJ had increased cell viability, growth, migration, G1-S transition, and 5-FU resistance. PTPRJ negatively regulated the JAK1 (show JAK1 Antibodies)/STAT3 (show STAT3 Antibodies) pathway by decreasing phosphorylation levels of JAK1 (show JAK1 Antibodies) and STAT3 (show STAT3 Antibodies) and expression of downstream factors.
The expression profiles of DEP1 and B2MG correlate with increased cell senescence and survival in breast cancer.
our results established DEP-1 as an essential driver of VEGF-dependent permeability, angiogenesis, and metastasis
DEP-1 acts as an endogenous antagonist of the insulin receptor (show INSR Antibodies), and downregulation of DEP-1 results in an improvement of insulin (show INS Antibodies) sensitivity.
Data indicate that CD148 mRNA is upregulated in diseased joints of with collagen-induced arthritis.
The large ectodomains of CD45 and CD148 modulate their inhibitory effect by enabling their passive, size-based segregation from ligated TCR, supporting the kinetic-segregation model of TCR triggering.
phosphatase CD148 promotes airway hyperresponsiveness through SRC (show SRC Antibodies) family kinases
These data indicate that PTPRJ may regulate differentiation of normal mammary epithelia and that dysregulation of protein localisation may be associated with tumorigenesis.
CD148 plays a dominant role in activating Src (show SRC Antibodies) family kinases in platelets relative to PTP-1B (show PTPN1 Antibodies). Both PTPs (show PTS Antibodies) are required for optimal platelet activation and aggregate formation under high arterial shear rates.
CD45 and CD148 preferentially target different SFK members (Hck and Fgr versus Lyn, respectively) to positively and negatively regulate GPCR pathways.
differential effects of CD148 in T cells and other leukocyte subsets
The protein encoded by this gene is a member of the protein tyrosine phosphatase (PTP) family. PTPs are known to be signaling molecules that regulate a variety of cellular processes, including cell growth, differentiation, mitotic cycle, and oncogenic transformation. This PTP possesses an extracellular region containing five fibronectin type III repeats, a single transmembrane region, and a single intracytoplasmic catalytic domain, and thus represents a receptor-type PTP. This protein is present in all hematopoietic lineages, and was shown to negatively regulate T cell receptor signaling possibly through interfering with the phosphorylation of Phospholipase C Gamma 1 and Linker for Activation of T Cells. This protein can also dephosphorylate the PDGF beta receptor, and may be involved in UV-induced signal transduction. Multiple transcript variants encoding different isoforms have been found for this gene.
receptor-type tyrosine-protein phosphatase eta
, density enhanced phosphatase-1
, protein tyrosine phosphatase, receptor type, J
, receptor-type tyrosine-protein phosphatase eta-like
, CD148 antigen
, HPTP eta
, density-enhanced phosphatase 1
, human density enhanced phosphatase-1
, protein tyrosine phosphatase, receptor type, J polypeptide
, protein-tyrosine phosphatase eta
, protein-tyrosine phosphatase receptor type J
, susceptibility to colon cancer 1, mouse, homolog of
, HPTP beta-like tyrosine phosphatase
, colon tumor susceptibility 1
, susceptibility to colon cancer 1
, supporting-cell antigen